In a previous study, we demonstrated that blockade of RANKL with anti‐RANKL mAb (IK22/5) improved anti‐metastatic and anti‐tumor activity achieved with antibodies targeting PD‐1/PD‐L1 in mouse models of melanoma and prostate cancer (Ahern15). Here, PDCD1 is linked to prostate cancer.